PDF(Sci-hub)
Abstract：
The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference-held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)-after the newest recommendations (2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery and Oral Pathology and Medicine, SICMF and SIPMO), written on the inputs of the experts of the Italian Allied Committee on ONJ (IAC-ONJ). The conference focused on the topic of MRONJ, and in particular on the common practices at risk of inappropriateness in MRONJ diagnosis and therapy, as well as on MRONJ prevention and the dental management of patients at risk of MRONJ. It is a matter of cancer and osteometabolic patients that are at risk since being exposed to several drugs with antiresorptive (i.e., bisphosphonates and denosumab) or, more recently, antiangiogenic activities. At the same time, the Conference traced for dentists and oral surgeons some easy applicable indications and procedures to reduce MRONJ onset risk and to diagnose it early. Continuous updating on these issues, so important for the patient community, is recommended.
摘要：
药物相关性颌骨坏死(MRONJ)的诊断过程及其预防发挥着越来越重要的作用,不仅取决于患者的生活质量(QoL)，而且还涉及大多数参与MRONJ预防（一级和二级）的牙医和口腔外科医生的决策过程。本文报告了在意大利口腔病理学与医学学会（SIPMO）研讨会上举行的共识会议（2018年10月20日，安科纳，意大利）-在两个科学学会（意大利颌面外科学会和口腔病理学与医学学会发表关于MRONJ的最新建议（2020年）之后，SICMF和SIPMO），根据意大利ONJ联盟委员会(IAC-ONJ)专家的意见编写。会议的重点是MRONJ，特别是关于MRONJ诊断和治疗中存在不适当风险的常见做法，以及MRONJ的预防和对MRONJ风险患者的牙科管理。这是一个癌症和骨代谢患者的问题，因为他们暴露于几种具有抗吸收性的药物(即，双膦酸盐和狄诺单抗)或，最近,抗血管生成活性。同时,会议为牙医和口腔外科医生追踪了一些简单适用的适应症和程序，以降低MRONJ发病风险并及早诊断。不断更新这些问题，对病人社区来说非常重要，是推荐的。
